Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Multiple Cancer Types

The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.
Leukemia, Pediatric Leukemia, Pediatrics
II
Friedman, Debra
NCT02927769
VICCPED1708

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: